Zimbabwe Pharmaceuticals & Healthcare Report

Published 11 December 2014

  • 85 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Zimbabwe Pharmaceuticals & Healthcare Report

BMI View: The World Health Organization's approval of a quality control laboratory for medicines in Zimbabwe is a positive step for the country's pharmaceutical market. It will help to reduce the proportion of counterfeit medicines in circulation and increase the country's attractiveness to multinational drugmakers. Nevertheless, for the foreseeable future the dire economic and political outlook, reduced healthcare budget and underdeveloped local manufacturing industry will continue to limit investment.

Headline Expenditure Projections

  • Pharmaceuticals: USD378mn in 2013 to USD388mn in 2014; +2.8% in US dollar terms. Forecast revised up from last quarter's projections to better suit current market conditions.

Risk/Reward Index

In BMI's RRI table for Q1 2015, Zimbabwe scores 29 out of 100, unchanged from the previous quarter. The country ranks 29th out of the 31 markets assessed in the Middle East and Africa (MEA) region.

Key Trends And Developments

November 2014

  • Patients are increasingly going to private medical institutions to receive medical attention due to a strike by doctors in public hospitals across Zimbabwe, reports allAfrica. The few available doctors at public hospitals in the country are only attending to emergency cases being brought to hospitals. There is less activity going on at government hospitals, compared with operations being carried out at private medical institutions, according to a study by The Herald. Patients at medical institutions, such as Avenues Clinic, Baines 24 Hour and West End have stated in separate interviews that they had to visit private institutions as they could not get help at public hospitals.

  • Under a private-public partnership initiative, more than 400 pharmacies in Zimbabwe have been authorised to sell anti-retrovirals (ARVs). The move has reduced the average cost of treatment at pharmacies by more than 50%. Under the new arrangements, the National AIDS Council (NAC) sources ARVs in bulk, and distributes them...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2010-2018)
16
Healthcare Market Forecast
16
Zimbabwe
17
Patented Drug Market Forecast
17
Generic Drug Market Forecast
18
Pharmaceutical Trade Forecast
19
Table: Pharmaceutical Trade Data And Forecasts (Zimbabwe 2012-2018)
20
Other Healthcare Data
20
Key Risks To BMI's Forecast Scenario
21
Macroeconomic Forecasts
23
Economic Activity
23
Table: GDP By Expenditure (Zimbabwe 2011-2018)
28
Industry Risk Reward Ratings
29
Middle East & Africa Risk/Reward Ratings
29
Zimbabwe Risk/Reward Ratings
36
Rewards
36
Risks
36
Market Overview
38
Industry Trends And Developments
39
Epidemiology
39
Healthcare Sector
43
Table: Zimbabwe: Healthcare Facilities
44
Healthcare Funding
45
Health Insurance
47
Healthcare Staff
48
Traditional Medicine
49
Biotechnology
49
Clinical Trials
50
Regulatory Development
51
Regulatory Regime
51
Intellectual Property Developments
53
Counterfeit Drugs
54
Pricing And Reimbursement Regimes
54
Public Drug Procurement
55
Competitive Landscape
57
Pharmaceutical Industry
57
Domestic Industry
58
Foreign Industry
59
Pharmaceutical Sector Developments
59
Retail Pharmacy Sector
61
Company Profile
62
Datlabs
62
Varichem Laboratories
64
Ranbaxy
68
Pfizer
70
Demographic Forecast
73
Table: Zimbabwe's Population By Age Group, 1990-2020 ('000)
74
Table: Zimbabwe's Population By Age Group, 1990-2020 (% of total)
75
Table: Zimbabwe's Key Population Ratios, 1990-2020
76
Table: Zimbabwe's Rural And Urban Population, 1990-2020
76
Glossary
77
Methodology
79
Pharmaceutical Expenditure Forecast Model
79
Healthcare Expenditure Forecast Model
79
Notes On Methodology
80
Risk/Reward Ratings Methodology
81
Ratings Overview
82
Table: Pharmaceutical Risk/Reward Ratings Indicators
82
Indicator Weightings
83

The Zimbabwe Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Zimbabwe Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Zimbabwe pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Zimbabwe, to test other views - a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Zimbabwean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Zimbabwe.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc